ACE and COVID-19: To date, however, there has been much debate about the relationship between the use of angiotensin-converting enzyme inhibitors (ACEi) and ARBs and the risk associated with COVID-19 (Devaux, 2020; Sama et al., 2020; Sriram and Insel, 2020; Zhang et al., 2020).